+Follow
Firehawk
No personal profile
1
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
Firehawk
2021-09-01
Nice
Sorry, the original content has been removed
Firehawk
2021-08-29
Interesting!
Sorry, the original content has been removed
Firehawk
2021-08-29
Nice
U.S. resumes supply of Lilly's COVID-19 antibody combo to some states
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4088656470277280","uuid":"4088656470277280","gmtCreate":1625553487440,"gmtModify":1625553487440,"name":"Firehawk","pinyin":"firehawk","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.04.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.30","exceedPercentage":"60.52%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":816365906,"gmtCreate":1630468479605,"gmtModify":1676530312121,"author":{"id":"4088656470277280","authorId":"4088656470277280","name":"Firehawk","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088656470277280","authorIdStr":"4088656470277280"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/816365906","repostId":"2163846863","repostType":4,"isVote":1,"tweetType":1,"viewCount":368,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813564192,"gmtCreate":1630216647516,"gmtModify":1676530245672,"author":{"id":"4088656470277280","authorId":"4088656470277280","name":"Firehawk","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088656470277280","authorIdStr":"4088656470277280"},"themes":[],"htmlText":"Interesting!","listText":"Interesting!","text":"Interesting!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/813564192","repostId":"2162521078","repostType":4,"isVote":1,"tweetType":1,"viewCount":374,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813564911,"gmtCreate":1630216603533,"gmtModify":1676530245664,"author":{"id":"4088656470277280","authorId":"4088656470277280","name":"Firehawk","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088656470277280","authorIdStr":"4088656470277280"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/813564911","repostId":"2162707824","repostType":4,"repost":{"id":"2162707824","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1630104635,"share":"https://ttm.financial/m/news/2162707824?lang=&edition=fundamental","pubTime":"2021-08-28 06:50","market":"us","language":"en","title":"U.S. resumes supply of Lilly's COVID-19 antibody combo to some states","url":"https://stock-news.laohu8.com/highlight/detail?id=2162707824","media":"Reuters","summary":"Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID","content":"<p>Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID-19 antibody cocktail to states where variants resistant to it are low, saying the therapy could work against the fast-spreading Delta variant based on lab studies.</p>\n<p>The Department of Health and Human Services narrowed the scope of authorization for the dual-antibody therapy, bamlanivimab and etesevimab, to states including Colorado, Connecticut and Illinois, Indiana.</p>\n<p>With the Delta variant becoming the dominant strain, the prevalence of variants resistant to the therapy is steadily decreasing, the agency said</p>\n<p>Based on lab tests, the drugs administered together are expected to retain activity against the Delta variant, but not against Delta plus and variants first identified in Brazil, South Africa and Colombia, it said.</p>\n<p>The department had in June paused its distribution after the therapy failed to show effectiveness against the coronavirus variants that were first identified in Brazil and South Africa.</p>\n<p>The supply of standalone etesevimab to be paired with existing supply of bamlanivimab is also being resumed to some states.</p>\n<p>Regeneron's antibody therapy REGEN-COV, and GlaxoSmithKline Plc and partner Vir Biotechnology's</p>\n<p>sotrovimab may be used in all states, territories, and U.S. jurisdictions as they are likely to be effective against most variants including Delta, the agency said.</p>\n<p>Bamlanivimab and etesevimab, REGEN-COV and sotrovimab are authorized for use in people 12 years and above with mild-to-moderate infection and are at high risk for progression to severe COVID-19.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. resumes supply of Lilly's COVID-19 antibody combo to some states</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. resumes supply of Lilly's COVID-19 antibody combo to some states\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-28 06:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID-19 antibody cocktail to states where variants resistant to it are low, saying the therapy could work against the fast-spreading Delta variant based on lab studies.</p>\n<p>The Department of Health and Human Services narrowed the scope of authorization for the dual-antibody therapy, bamlanivimab and etesevimab, to states including Colorado, Connecticut and Illinois, Indiana.</p>\n<p>With the Delta variant becoming the dominant strain, the prevalence of variants resistant to the therapy is steadily decreasing, the agency said</p>\n<p>Based on lab tests, the drugs administered together are expected to retain activity against the Delta variant, but not against Delta plus and variants first identified in Brazil, South Africa and Colombia, it said.</p>\n<p>The department had in June paused its distribution after the therapy failed to show effectiveness against the coronavirus variants that were first identified in Brazil and South Africa.</p>\n<p>The supply of standalone etesevimab to be paired with existing supply of bamlanivimab is also being resumed to some states.</p>\n<p>Regeneron's antibody therapy REGEN-COV, and GlaxoSmithKline Plc and partner Vir Biotechnology's</p>\n<p>sotrovimab may be used in all states, territories, and U.S. jurisdictions as they are likely to be effective against most variants including Delta, the agency said.</p>\n<p>Bamlanivimab and etesevimab, REGEN-COV and sotrovimab are authorized for use in people 12 years and above with mild-to-moderate infection and are at high risk for progression to severe COVID-19.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","VIR":"Vir Biotechnology, Inc.","REGN":"再生元制药公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162707824","content_text":"Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID-19 antibody cocktail to states where variants resistant to it are low, saying the therapy could work against the fast-spreading Delta variant based on lab studies.\nThe Department of Health and Human Services narrowed the scope of authorization for the dual-antibody therapy, bamlanivimab and etesevimab, to states including Colorado, Connecticut and Illinois, Indiana.\nWith the Delta variant becoming the dominant strain, the prevalence of variants resistant to the therapy is steadily decreasing, the agency said\nBased on lab tests, the drugs administered together are expected to retain activity against the Delta variant, but not against Delta plus and variants first identified in Brazil, South Africa and Colombia, it said.\nThe department had in June paused its distribution after the therapy failed to show effectiveness against the coronavirus variants that were first identified in Brazil and South Africa.\nThe supply of standalone etesevimab to be paired with existing supply of bamlanivimab is also being resumed to some states.\nRegeneron's antibody therapy REGEN-COV, and GlaxoSmithKline Plc and partner Vir Biotechnology's\nsotrovimab may be used in all states, territories, and U.S. jurisdictions as they are likely to be effective against most variants including Delta, the agency said.\nBamlanivimab and etesevimab, REGEN-COV and sotrovimab are authorized for use in people 12 years and above with mild-to-moderate infection and are at high risk for progression to severe COVID-19.","news_type":1},"isVote":1,"tweetType":1,"viewCount":464,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":813564911,"gmtCreate":1630216603533,"gmtModify":1676530245664,"author":{"id":"4088656470277280","authorId":"4088656470277280","name":"Firehawk","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088656470277280","authorIdStr":"4088656470277280"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/813564911","repostId":"2162707824","repostType":4,"repost":{"id":"2162707824","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1630104635,"share":"https://ttm.financial/m/news/2162707824?lang=&edition=fundamental","pubTime":"2021-08-28 06:50","market":"us","language":"en","title":"U.S. resumes supply of Lilly's COVID-19 antibody combo to some states","url":"https://stock-news.laohu8.com/highlight/detail?id=2162707824","media":"Reuters","summary":"Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID","content":"<p>Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID-19 antibody cocktail to states where variants resistant to it are low, saying the therapy could work against the fast-spreading Delta variant based on lab studies.</p>\n<p>The Department of Health and Human Services narrowed the scope of authorization for the dual-antibody therapy, bamlanivimab and etesevimab, to states including Colorado, Connecticut and Illinois, Indiana.</p>\n<p>With the Delta variant becoming the dominant strain, the prevalence of variants resistant to the therapy is steadily decreasing, the agency said</p>\n<p>Based on lab tests, the drugs administered together are expected to retain activity against the Delta variant, but not against Delta plus and variants first identified in Brazil, South Africa and Colombia, it said.</p>\n<p>The department had in June paused its distribution after the therapy failed to show effectiveness against the coronavirus variants that were first identified in Brazil and South Africa.</p>\n<p>The supply of standalone etesevimab to be paired with existing supply of bamlanivimab is also being resumed to some states.</p>\n<p>Regeneron's antibody therapy REGEN-COV, and GlaxoSmithKline Plc and partner Vir Biotechnology's</p>\n<p>sotrovimab may be used in all states, territories, and U.S. jurisdictions as they are likely to be effective against most variants including Delta, the agency said.</p>\n<p>Bamlanivimab and etesevimab, REGEN-COV and sotrovimab are authorized for use in people 12 years and above with mild-to-moderate infection and are at high risk for progression to severe COVID-19.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. resumes supply of Lilly's COVID-19 antibody combo to some states</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. resumes supply of Lilly's COVID-19 antibody combo to some states\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-28 06:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID-19 antibody cocktail to states where variants resistant to it are low, saying the therapy could work against the fast-spreading Delta variant based on lab studies.</p>\n<p>The Department of Health and Human Services narrowed the scope of authorization for the dual-antibody therapy, bamlanivimab and etesevimab, to states including Colorado, Connecticut and Illinois, Indiana.</p>\n<p>With the Delta variant becoming the dominant strain, the prevalence of variants resistant to the therapy is steadily decreasing, the agency said</p>\n<p>Based on lab tests, the drugs administered together are expected to retain activity against the Delta variant, but not against Delta plus and variants first identified in Brazil, South Africa and Colombia, it said.</p>\n<p>The department had in June paused its distribution after the therapy failed to show effectiveness against the coronavirus variants that were first identified in Brazil and South Africa.</p>\n<p>The supply of standalone etesevimab to be paired with existing supply of bamlanivimab is also being resumed to some states.</p>\n<p>Regeneron's antibody therapy REGEN-COV, and GlaxoSmithKline Plc and partner Vir Biotechnology's</p>\n<p>sotrovimab may be used in all states, territories, and U.S. jurisdictions as they are likely to be effective against most variants including Delta, the agency said.</p>\n<p>Bamlanivimab and etesevimab, REGEN-COV and sotrovimab are authorized for use in people 12 years and above with mild-to-moderate infection and are at high risk for progression to severe COVID-19.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","VIR":"Vir Biotechnology, Inc.","REGN":"再生元制药公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162707824","content_text":"Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID-19 antibody cocktail to states where variants resistant to it are low, saying the therapy could work against the fast-spreading Delta variant based on lab studies.\nThe Department of Health and Human Services narrowed the scope of authorization for the dual-antibody therapy, bamlanivimab and etesevimab, to states including Colorado, Connecticut and Illinois, Indiana.\nWith the Delta variant becoming the dominant strain, the prevalence of variants resistant to the therapy is steadily decreasing, the agency said\nBased on lab tests, the drugs administered together are expected to retain activity against the Delta variant, but not against Delta plus and variants first identified in Brazil, South Africa and Colombia, it said.\nThe department had in June paused its distribution after the therapy failed to show effectiveness against the coronavirus variants that were first identified in Brazil and South Africa.\nThe supply of standalone etesevimab to be paired with existing supply of bamlanivimab is also being resumed to some states.\nRegeneron's antibody therapy REGEN-COV, and GlaxoSmithKline Plc and partner Vir Biotechnology's\nsotrovimab may be used in all states, territories, and U.S. jurisdictions as they are likely to be effective against most variants including Delta, the agency said.\nBamlanivimab and etesevimab, REGEN-COV and sotrovimab are authorized for use in people 12 years and above with mild-to-moderate infection and are at high risk for progression to severe COVID-19.","news_type":1},"isVote":1,"tweetType":1,"viewCount":464,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":816365906,"gmtCreate":1630468479605,"gmtModify":1676530312121,"author":{"id":"4088656470277280","authorId":"4088656470277280","name":"Firehawk","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088656470277280","authorIdStr":"4088656470277280"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/816365906","repostId":"2163846863","repostType":4,"repost":{"id":"2163846863","kind":"highlight","pubTimestamp":1630461060,"share":"https://ttm.financial/m/news/2163846863?lang=&edition=fundamental","pubTime":"2021-09-01 09:51","market":"us","language":"en","title":"Disney World Won't Be Quiet for Long","url":"https://stock-news.laohu8.com/highlight/detail?id=2163846863","media":"Motley Fool","summary":"The top theme park operator is reportedly going through a lull in attendance, but it's all about to change.","content":"<blockquote>\n <b>The top theme park operator is reportedly going through a lull in attendance, but it's all about to change.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Several popular blogs and enthusiast sites are writing about Disney World crowd levels being at their lowest levels of the year.</li>\n <li>Crowds and ticket prices will be moving higher come October as the resort kicks off an 18-month celebration for Disney World turning 50.</li>\n <li>Even in the lull, it's been able to sell out its premium-priced Halloween event through all of August and September. It's not at risk of squandering its return to profitability.</li>\n</ul>\n<p>It's the calm before the storm. <b>Walt Disney</b>'s (NYSE:DIS) typically busy Disney World resort has been surprisingly quiet lately, according to many of the leading trip-planning sites and theme park blogs.</p>\n<p>Touring Plans -- a subscription-based crowd level-tracking specialist -- recently revised its forecasts lower across all four Disney World gated attractions through the end of September. Other fandom outlets including AllEars.Net, BlogMickey, Inside the Magic, and <i>Attractions Magazine</i> have written about the surprisingly low wait times on even some of the popular rides.</p>\n<p>It's not going to last, of course. Let's check out some of the reasons why the days are numbered for the current slow season at the world's most visited theme park resort.</p>\n<p><img src=\"https://static.tigerbbs.com/248fbf703c5964332bce9b1d1d2a40de\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Disney.</p>\n<h3>Love in a roller coaster</h3>\n<p>If you're a Disney shareholder, don't panic. The same company that surprised the market with a return to profitability for its theme parks segment in its latest quarter isn't going to be seeing red on its bottom line anytime soon.</p>\n<p>The theme parks seeing what Disney Tourist Blog is calling the weakest crowds of the year right now isn't really a surprise. Florida schools started up again two weeks ago, so weekday crowds will naturally be light with most young families out of the mix. We also can't forget that the delta variant has been wreaking havoc on Florida's COVID-19 case counts, hospitalization rates, viral positivity rates, and deaths. Between the obvious safety concerns and the return of indoor masking mandates making visits less than ideal for some, it's not a shock to see both locals and tourists not as eager to visit the House of Mouse as they were earlier in the summer.</p>\n<p>Another point to consider is that many Disney rides and attractions that were spacing guests out earlier this year -- reducing the hourly capacity levels -- are back to normal. In short, lower wait times for rides doesn't mean that the park attendance levels are at the lowest point of 2021. It's just more efficient now that Disney's eased up on having empty seats between groups of riders and taking breaks to clean the vehicles.</p>\n<p>Finally, we have Disney World turning 50 soon. The world's most visited theme park resort opened on Oct. 1, 1971, and come October it will be starting an 18-month-long celebration. New nighttime shows, in-park events, and even the official opening of a new ride will kick things off in October. If you were planning a trip to Disney World in the next few weeks, why not put it off until October?</p>\n<p>Financially speaking, Disney World isn't going through a dry spell. Crowds may seem light right now, but Disney After Hours Boo Bash -- a Halloween-themed event taking place on select nights at the Magic Kingdom -- is sold out despite being shorter and more expensive than it was during the more expansive Halloween after-hours party it hosted two years ago.</p>\n<p>It also won't be just the crowds coming in October. Disney will be making a lot more per turnstile click. A single-day ticket to any of Disney World's four theme parks will cost you $109 today or most of the weekdays in September. Come October, the cheapest <a href=\"https://laohu8.com/S/AONE.U\">one</a>-day ticket will be $126, and after Labor Day you'll be paying at $133 for a day at the gated attraction of your choice.</p>\n<p>Disney is also resuming annual pass sales next week at higher price points than before. Some of the previously included features will now only available as premium upcharge items, including the Disney Genie+ plan that has ruffled feathers in the enthusiast community.</p>\n<p>So don't let the light crowds the past couple of weeks make you nervous about Disney's financials. The travel and tourism stock bellwether is just catching its breath before its plan to make more money with fewer guests gets rolling.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Disney World Won't Be Quiet for Long</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDisney World Won't Be Quiet for Long\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-01 09:51 GMT+8 <a href=https://www.fool.com/investing/2021/08/31/disney-world-wont-be-quiet-for-long/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The top theme park operator is reportedly going through a lull in attendance, but it's all about to change.\n\nKey Points\n\nSeveral popular blogs and enthusiast sites are writing about Disney World crowd...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/31/disney-world-wont-be-quiet-for-long/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIS":"迪士尼"},"source_url":"https://www.fool.com/investing/2021/08/31/disney-world-wont-be-quiet-for-long/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2163846863","content_text":"The top theme park operator is reportedly going through a lull in attendance, but it's all about to change.\n\nKey Points\n\nSeveral popular blogs and enthusiast sites are writing about Disney World crowd levels being at their lowest levels of the year.\nCrowds and ticket prices will be moving higher come October as the resort kicks off an 18-month celebration for Disney World turning 50.\nEven in the lull, it's been able to sell out its premium-priced Halloween event through all of August and September. It's not at risk of squandering its return to profitability.\n\nIt's the calm before the storm. Walt Disney's (NYSE:DIS) typically busy Disney World resort has been surprisingly quiet lately, according to many of the leading trip-planning sites and theme park blogs.\nTouring Plans -- a subscription-based crowd level-tracking specialist -- recently revised its forecasts lower across all four Disney World gated attractions through the end of September. Other fandom outlets including AllEars.Net, BlogMickey, Inside the Magic, and Attractions Magazine have written about the surprisingly low wait times on even some of the popular rides.\nIt's not going to last, of course. Let's check out some of the reasons why the days are numbered for the current slow season at the world's most visited theme park resort.\n\nImage source: Disney.\nLove in a roller coaster\nIf you're a Disney shareholder, don't panic. The same company that surprised the market with a return to profitability for its theme parks segment in its latest quarter isn't going to be seeing red on its bottom line anytime soon.\nThe theme parks seeing what Disney Tourist Blog is calling the weakest crowds of the year right now isn't really a surprise. Florida schools started up again two weeks ago, so weekday crowds will naturally be light with most young families out of the mix. We also can't forget that the delta variant has been wreaking havoc on Florida's COVID-19 case counts, hospitalization rates, viral positivity rates, and deaths. Between the obvious safety concerns and the return of indoor masking mandates making visits less than ideal for some, it's not a shock to see both locals and tourists not as eager to visit the House of Mouse as they were earlier in the summer.\nAnother point to consider is that many Disney rides and attractions that were spacing guests out earlier this year -- reducing the hourly capacity levels -- are back to normal. In short, lower wait times for rides doesn't mean that the park attendance levels are at the lowest point of 2021. It's just more efficient now that Disney's eased up on having empty seats between groups of riders and taking breaks to clean the vehicles.\nFinally, we have Disney World turning 50 soon. The world's most visited theme park resort opened on Oct. 1, 1971, and come October it will be starting an 18-month-long celebration. New nighttime shows, in-park events, and even the official opening of a new ride will kick things off in October. If you were planning a trip to Disney World in the next few weeks, why not put it off until October?\nFinancially speaking, Disney World isn't going through a dry spell. Crowds may seem light right now, but Disney After Hours Boo Bash -- a Halloween-themed event taking place on select nights at the Magic Kingdom -- is sold out despite being shorter and more expensive than it was during the more expansive Halloween after-hours party it hosted two years ago.\nIt also won't be just the crowds coming in October. Disney will be making a lot more per turnstile click. A single-day ticket to any of Disney World's four theme parks will cost you $109 today or most of the weekdays in September. Come October, the cheapest one-day ticket will be $126, and after Labor Day you'll be paying at $133 for a day at the gated attraction of your choice.\nDisney is also resuming annual pass sales next week at higher price points than before. Some of the previously included features will now only available as premium upcharge items, including the Disney Genie+ plan that has ruffled feathers in the enthusiast community.\nSo don't let the light crowds the past couple of weeks make you nervous about Disney's financials. The travel and tourism stock bellwether is just catching its breath before its plan to make more money with fewer guests gets rolling.","news_type":1},"isVote":1,"tweetType":1,"viewCount":368,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813564192,"gmtCreate":1630216647516,"gmtModify":1676530245672,"author":{"id":"4088656470277280","authorId":"4088656470277280","name":"Firehawk","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088656470277280","authorIdStr":"4088656470277280"},"themes":[],"htmlText":"Interesting!","listText":"Interesting!","text":"Interesting!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/813564192","repostId":"2162521078","repostType":4,"repost":{"id":"2162521078","kind":"news","pubTimestamp":1630095343,"share":"https://ttm.financial/m/news/2162521078?lang=&edition=fundamental","pubTime":"2021-08-28 04:15","market":"us","language":"en","title":"S&P 500, Nasdaq nab all-time closing highs as Powell soothes taper fears","url":"https://stock-news.laohu8.com/highlight/detail?id=2162521078","media":"Reuters","summary":"NEW YORK, Aug 27 (Reuters) - Wall Street rallied on Friday, pushing the S&P and the Nasdaq to record","content":"<p>NEW YORK, Aug 27 (Reuters) - Wall Street rallied on Friday, pushing the S&P and the Nasdaq to record closing highs for the fourth time this week, as U.S. Federal Reserve Chairman Jerome Powell's remarks at the Jackson Hole Symposium calmed fears over the tapering timetable and sent investors into the weekend in a buying mood.</p>\n<p>All three indexes posted weekly gains.</p>\n<p>\"I see two things happening,\" said Mike Zigmont, head of research and trading at Harvest Volatility Management in New York. \"I see a reflexive dip-buying validation and I see the market embracing a dovish Fed.\"</p>\n<p>Regarding the indexes' recent string of all-time highs, including the S&P 500's 52nd record high close so far this year, Zigmont said \"The march north has been very consistent. The drawdowns are super shallow, and the recoveries are very fast.\"</p>\n<p>In his prepared remarks, Powell stopped short of providing a clearer picture regarding the timing of the central bank's tapering of asset purchases or hiking interest rates, the key elements of its dovish monetary policy aimed at helping the economy recover from the pandemic recession.</p>\n<p>Indeed, Powell appeared to strike a more dovish tone than other Federal Open Market Committee (FOMC) officials, including St. Louis Fed President James Bullard and Cleveland Fed President Loretta Mester, who said earlier in the day that they expect the tapering process to begin soon and wind down next year.</p>\n<p>\"The market is very happy that the Fed is pumping more liquidity into the economy every month,\" Zigmont added. \"The Fed is enabling asset prices to climb and the market is pleased with that.\"</p>\n<p>Economic data released on Friday delivered, in large part, precisely what economists expected - a pullback in consumer spending and sentiment due to the COVID-19 Delta variant, and signs that the current wave of price spikes will not morph into long term inflation, inline with Fed assurances.</p>\n<p>The Dow Jones Industrial Average rose 242.68 points, or 0.69%, to 35,455.8, the S&P 500 gained 39.37 points, or 0.88%, to 4,509.37 and the Nasdaq Composite added 183.69 points, or 1.23%, to 15,129.50.</p>\n<p>Ten of the 11 major sectors of the S&P 500 advanced, with energy shares enjoying the largest percentage gain.</p>\n<p>Chipmaker Nvidia's shares rose 2.6% after sources said it would likely seek antitrust approval from the European Union to take over British chip designer Arm.</p>\n<p><a href=\"https://laohu8.com/S/WDAY\">Workday</a> Inc jumped 9.1% as brokerages upped their price targets after the company beat second-quarter revenue estimates.</p>\n<p>Stay-at-home darling Peloton Interactive Inc slid 8.5% following its profit warning and its announcement it was being probed by U.S. regulators over an accident involving the safety of its treadmills.</p>\n<p>U.S.-listed shares of Alibaba Group and Tencent Music Entertainment fell 3.5% and 1.4%, respectively, while the Invesco Golden Dragon ETF dropped 1.1%.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 5.21-to-1 ratio; on Nasdaq, a 3.40-to-1 ratio favored advancers.</p>\n<p>The S&P 500 posted 60 new 52-week highs and <a href=\"https://laohu8.com/S/AONE.U\">one</a> new low; the Nasdaq Composite recorded 132 new highs and 37 new lows.</p>\n<p>Volume on U.S. exchanges was 8.67 billion shares, compared with the 8.95 billion average over the last 20 trading days. </p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500, Nasdaq nab all-time closing highs as Powell soothes taper fears</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500, Nasdaq nab all-time closing highs as Powell soothes taper fears\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-28 04:15 GMT+8 <a href=https://finance.yahoo.com/news/us-stocks-p-500-nasdaq-201543085.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK, Aug 27 (Reuters) - Wall Street rallied on Friday, pushing the S&P and the Nasdaq to record closing highs for the fourth time this week, as U.S. Federal Reserve Chairman Jerome Powell's ...</p>\n\n<a href=\"https://finance.yahoo.com/news/us-stocks-p-500-nasdaq-201543085.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","OEF":"标普100指数ETF-iShares","UPRO":"三倍做多标普500ETF","SH":"标普500反向ETF","SSO":"两倍做多标普500ETF","POWL":"Powell Industries","OEX":"标普100","SPY":"标普500ETF",".SPX":"S&P 500 Index","COMP":"Compass, Inc.","SPXU":"三倍做空标普500ETF","SDS":"两倍做空标普500ETF","IVV":"标普500指数ETF"},"source_url":"https://finance.yahoo.com/news/us-stocks-p-500-nasdaq-201543085.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2162521078","content_text":"NEW YORK, Aug 27 (Reuters) - Wall Street rallied on Friday, pushing the S&P and the Nasdaq to record closing highs for the fourth time this week, as U.S. Federal Reserve Chairman Jerome Powell's remarks at the Jackson Hole Symposium calmed fears over the tapering timetable and sent investors into the weekend in a buying mood.\nAll three indexes posted weekly gains.\n\"I see two things happening,\" said Mike Zigmont, head of research and trading at Harvest Volatility Management in New York. \"I see a reflexive dip-buying validation and I see the market embracing a dovish Fed.\"\nRegarding the indexes' recent string of all-time highs, including the S&P 500's 52nd record high close so far this year, Zigmont said \"The march north has been very consistent. The drawdowns are super shallow, and the recoveries are very fast.\"\nIn his prepared remarks, Powell stopped short of providing a clearer picture regarding the timing of the central bank's tapering of asset purchases or hiking interest rates, the key elements of its dovish monetary policy aimed at helping the economy recover from the pandemic recession.\nIndeed, Powell appeared to strike a more dovish tone than other Federal Open Market Committee (FOMC) officials, including St. Louis Fed President James Bullard and Cleveland Fed President Loretta Mester, who said earlier in the day that they expect the tapering process to begin soon and wind down next year.\n\"The market is very happy that the Fed is pumping more liquidity into the economy every month,\" Zigmont added. \"The Fed is enabling asset prices to climb and the market is pleased with that.\"\nEconomic data released on Friday delivered, in large part, precisely what economists expected - a pullback in consumer spending and sentiment due to the COVID-19 Delta variant, and signs that the current wave of price spikes will not morph into long term inflation, inline with Fed assurances.\nThe Dow Jones Industrial Average rose 242.68 points, or 0.69%, to 35,455.8, the S&P 500 gained 39.37 points, or 0.88%, to 4,509.37 and the Nasdaq Composite added 183.69 points, or 1.23%, to 15,129.50.\nTen of the 11 major sectors of the S&P 500 advanced, with energy shares enjoying the largest percentage gain.\nChipmaker Nvidia's shares rose 2.6% after sources said it would likely seek antitrust approval from the European Union to take over British chip designer Arm.\nWorkday Inc jumped 9.1% as brokerages upped their price targets after the company beat second-quarter revenue estimates.\nStay-at-home darling Peloton Interactive Inc slid 8.5% following its profit warning and its announcement it was being probed by U.S. regulators over an accident involving the safety of its treadmills.\nU.S.-listed shares of Alibaba Group and Tencent Music Entertainment fell 3.5% and 1.4%, respectively, while the Invesco Golden Dragon ETF dropped 1.1%.\nAdvancing issues outnumbered declining ones on the NYSE by a 5.21-to-1 ratio; on Nasdaq, a 3.40-to-1 ratio favored advancers.\nThe S&P 500 posted 60 new 52-week highs and one new low; the Nasdaq Composite recorded 132 new highs and 37 new lows.\nVolume on U.S. exchanges was 8.67 billion shares, compared with the 8.95 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":374,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
